Mode
Text Size
Log in / Sign up
Phase 3 N=7,466 Randomized Triple-blind Prevention

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Cervical Cancer · Precancerous Condition

Enrolled (actual)
7,466
Serious AEs
24.2%
Results posted
May 2012
Primary outcome: Primary: Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen. — 1; 9; 0; 2 Events

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine (Biological); hepatitis A inactivated virus vaccine (Biological)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
GlaxoSmithKline
Primary completion
Dec 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.
1; 9; 0; 2; 1; 10
SECONDARY
Number of Cervical Infection With HPV16 or HPV18.
13; 77; 10; 57; 22; 118
SECONDARY
Number of Histopathologically Confirmed CIN2+ Cases Associated With Infection by Any Oncogenic HPV Type
1; 9; 0; 2; 1; 6
SECONDARY
Number of Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 Cases
10; 71; 0; 37; 10; 104
SECONDARY
Geometric Mean Titers (GMTs) for HPV-16 Antibody in the Immunogenicity Subcohort.
6.7; 8.2; 646.6; 7.9; 771.5; 8.4
SECONDARY
Geometric Mean Titers (GMTs) for HPV-18 Antibody in the Immunogenicity Subcohort
5.4; 6.2; 372.7; 6.4; 532.2; 6.7
SECONDARY
HPV-16 Geometric Mean Titers (GMTs) (V5 Monoclonal Antibody Inhibition Test)
21.1; 21.4; 58.5; 21.5; 80.9; 21.5
SECONDARY
HPV-18 Geometric Mean Titers (GMTs) (J4 Monoclonal Antibody Inhibition Test)
55.0; 55.7; 99.1; 55.3; 111.4; 55.4
SECONDARY
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.
1627; 1610; 25; 20; 544; 501
SECONDARY
Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms.
512; 502; 6; 5; 257; 232
SECONDARY
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms on a 10% Random Subset of Participants.
202; 74; 0; 0; 6; 1
SECONDARY
Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms on a 10% Random Subset of Participants.
214; 189; 2; 0; 250; 211
SECONDARY
Number of Subjects Reporting Serious Adverse Events (SAEs).
912; 891
SECONDARY
Number of Subjects Reporting Unsolicited Adverse Events (AEs).
1638; 1536
SECONDARY
Number of Subjects With All Possible Pregnancy Outcomes
317; 294; 1756; 1766; 50; 69
SECONDARY
Number of Cervical Infection With HPV16 or HPV18.
13; 77; 10; 57; 22; 118
SECONDARY
Number of Cervical Infection With HPV16 or HPV18.
13; 77; 10; 57; 22; 118
SECONDARY
Number of Cervical Infection With HPV16 or HPV18.
13; 77; 10; 57; 22; 118
SECONDARY
Number of Cervical Infection With HPV16 or HPV18.
13; 77; 10; 57; 22; 118
SECONDARY
Number of Subjects Reporting Unsolicited Adverse Events (AEs).
1638; 1536

Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in preventing cervical intraepithelial neoplasia or cervical cancer. It is not yet known whether human papillomavirus vaccine is more effective than hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer. PURPOSE: This randomized phase III trial is studying human papillomavirus vaccine to see how well it works compared to hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer in younger healthy participants.

Eligibility Criteria

DISEASE CHARACTERISTICS:

•Healthy participants

  • Deemed to be in good general health by history and physical examination

•Resident of Guanacaste Province of Costa Rica and surrounding areas

  • Must remain a resident for ≥ 6 months after the first study vaccination

PATIENT CHARACTERISTICS:

Age

  • 18 to 25

Performance status

•Not specified

Life expectancy

•Not specified

Hematopoietic

•Not specified

Hepatic

  • No history of chronic hepatitis requiring treatment
  • No acute or chronic clinically significant hepatic function abnormality by physical examination or laboratory findings
  • No known history of hepatitis A infection

Renal

  • No history of kidney disease requiring treatment
  • No acute or chronic clinically significant kidney function abnormality by physical examination or laboratory findings

Cardiovascular

  • No acute or chronic clinically significant cardiovascular function abnormality by physical examination or laboratory findings Pulmonary
  • No acute or chronic clinically significant pulmonary function abnormality by physical examination or laboratory findings Immunology
  • No history of allergic disease
  • No history of autoimmune disorder requiring treatment
  • No history of allergic reaction (e.g., difficulty breathing) to any vaccine
  • No suspected allergy or reaction likely to be exacerbated by a component of the study vaccines (e.g., 2-phenoxyethanol or neomycin)
  • No hypersensitivity to latex
  • No diagnosis or suspicion of any immunodeficient condition by medical history or physical examination Other
  • Not pregnant or nursing

◦No delivery within the past 3 months

  • Negative pregnancy test
  • Fertile patients must use effective contraception for 30 days before, during, and for 60 days after completion of study treatment
  • Able to speak or understand Spanish
  • Mentally competent
  • Able to undergo pelvic exam (i.e., no heavy bleeding [menstruation or otherwise] or heavy vaginal discharge)
  • No history of cancer requiring treatment
  • No history of diabetes requiring treatment
  • No history of other chronic conditions requiring treatment
  • No acute or chronic clinically significant neurologic function abnormality by physical examination or laboratory findings
  • No other acute disease
  • No fever ≥ 37.5º C

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • More than 6 months since prior chronic administration (i.e., > 14 days) of immune-modulating drugs
  • More than 90 days since prior immunoglobulins
  • More than 30 days since prior and no other concurrent investigational or non-registered vaccines
  • More than 30 days since prior registered vaccines
  • More than 8 days since prior routine meningococcal, hepatitis B, influenza, or diphtheria/tetanus vaccine
  • No prior vaccination against hepatitis A
  • No prior vaccination against human papillomavirus
  • No prior monophosphoryl lipid A or AS04 adjuvant

Chemotherapy

•Not specified

Endocrine therapy

  • More than 6 months since prior chronic administration (i.e., > 14 days) of corticosteroids (e.g., ≥ 0.5 mg/kg/day of prednisone or equivalent)
  • Concurrent inhaled or topical steroids allowed

Radiotherapy

•Not specified

Surgery

•No prior hysterectomy

Other

  • More than 6 months since prior chronic administration (i.e., > 14 days) of immunosuppressants
  • More than 30 days since prior and no other concurrent investigational or non-registered drugs
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00128661). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search